Table N-7, Sexual function outcomes by age subgroups - Menopausal Symptoms: Comparative Effectiveness of Therapies

Warning: The NCBI web site requires JavaScript to function. more...

Trial	Outcome	Subgroup	Treatment	N	Results
Brunner, 2005, United States	Mean change in satisfaction score^a	Age 50-54 with MSVS	Placebo	134	0.02 (SD: 1.2)

			0.625 mg CEE	140	-0.07 (SD: 1.1)^b

Hays, 2003, United States	Mean change in satisfaction score^a	Age 50-54 with MSVS	Placebo	201	-0.2 (SD: 1.3)

			0.625 mg CEE + 2.5 mg MPA	221	0.1 (SD: 1.2)^c

Davis, 2001, Australia	Difference in MENQOL sex score from placebo	Age < 55	Placebo	NR	-
		Age < 55	Chinese herbs	NR	-0.72 (95% CI: -2.8 to 1.4)

		Age ≥ 55	Placebo	NR	-
		Age ≥ 55	Chinese herbs	NR	-0.14 (95% CI: -1.3 to 1.0)

Rigano, 2001, Italy	Percent reporting decrease in sexual activity	Age 48-50	Placebo	75	44%
		Age 48-50	0.05 mg estradiol	88	48%

		Age 51-53	Placebo	61	62%
		Age 51-53	0.05 mg estradiol	52	75%

		Age 54-56	Placebo	55	48%
		Age 54-56	0.05 mg estradiol	31	84%

: CEE: conjugated equine estrogen; MENQOL: Menopause-specific Quality of Life; MPA: medroxyprogesterone acetate; MSV: moderate to severe vasomotor symptoms; NR: not reported
a: Satisfaction score from a single question: 1=’very unsatisfied’ to 4=’very satisfied’
b: difference between groups: p=0.50
c: difference between groups: p=0.06

Menopausal Symptoms: Comparative Effectiveness of Therapies [Internet].

Comparative Effectiveness Reviews, No. 147.

Grant MD, Marbella A, Wang AT, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.